Trials / Completed
CompletedNCT03971929
Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension
A Phase I, Randomized, Double-Blind, Placebo-hydrochlorothiazide Parallel Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Efficacy of SHR 0532 Oral Tablets in Mild Hypertension Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the safety and efficacy and Pharmacokinetics/Pharmacodynamics of SHR0532 in subjects with mild hypertension for 4 weeks.
Detailed description
This is a randomized, double-blind, multiple ascending dose, placebo- and Hydrochlorothiazide-controlled study to evaluate the safety and tolerability, Pharmacokinetics and Pharmacodynamics and effect on blood pressure of SHR0532 tablets in patients with mild hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR0532 | once daily(QD) for 4weeks |
| DRUG | SHR placebo | once daily(QD) for 4weeks |
| DRUG | Hydrochlorothiazide 25 mg | once daily(QD) for 4weeks |
Timeline
- Start date
- 2019-07-31
- Primary completion
- 2020-09-03
- Completion
- 2020-09-03
- First posted
- 2019-06-03
- Last updated
- 2021-10-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03971929. Inclusion in this directory is not an endorsement.